ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000A43

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Identifieur interne : 000A43 ( PascalFrancis/Corpus ); précédent : 000A42; suivant : 000A44

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Auteurs : Alan L. Whone ; Ray L. Watts ; A. Jon Stoessl ; Margaret Davis ; Sven Reske ; Claude Nahmias ; Anthony E. Lang ; Olivier Rascol ; Maria J. Ribeiro ; Philippe Remy ; Werner H. Poewe ; Robert A. Hauser ; David J. Brooks

Source :

Annals of neurology [ 0364-5134 ] ; 2003.

RBID : Pascal:03-0498653

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Ropinirole, Tomoscintigraphie, Dopa, Dopamine, Putamen, Cartographie, Etude comparative, Lévodopa, Positon, Stimulant dopaminergique, Etude double insu, Homme, Pronostic, Agoniste, Récepteur dopaminergique D2, Aminoacide, Catécholamine, Captation.

English descriptors

KwdEn :
- Agonist, Aminoacid, Cartography, Catecholamine, Comparative study, D2 Dopamine receptor, Dopa, Dopamine, Dopamine agonist, Double blind study, Emission tomography, Human, Levodopa, Parkinson disease, Positron, Prognosis, Putamen, Ropinirole, Uptake.

Abstract

Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using ¹⁸F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and ¹⁸F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen ¹⁸F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in ¹⁸F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by ¹⁸F-dopa PET.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0364-5134`
A02	`01`			`@0 ANNED3`
A03		`1`		`@0 Ann. neurol.`
A05				`@2 54`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study`
A11	`01`	`1`		`@1 WHONE (Alan L.)`
A11	`02`	`1`		`@1 WATTS (Ray L.)`
A11	`03`	`1`		`@1 STOESSL (A. Jon)`
A11	`04`	`1`		`@1 DAVIS (Margaret)`
A11	`05`	`1`		`@1 RESKE (Sven)`
A11	`06`	`1`		`@1 NAHMIAS (Claude)`
A11	`07`	`1`		`@1 LANG (Anthony E.)`
A11	`08`	`1`		`@1 RASCOL (Olivier)`
A11	`09`	`1`		`@1 RIBEIRO (Maria J.)`
A11	`10`	`1`		`@1 REMY (Philippe)`
A11	`11`	`1`		`@1 POEWE (Werner H.)`
A11	`12`	`1`		`@1 HAUSER (Robert A.)`
A11	`13`	`1`		`@1 BROOKS (David J.)`
A14	`01`			`@1 Faculty of Medicine, Imperial College, Hammersmith Hospital @2 London @3 GBR @Z 1 aut. @Z 13 aut.`
A14	`02`			`@1 Department of Neurology, Emory University School of Medicine @2 Atlanta, GA @3 USA @Z 2 aut. @Z 4 aut.`
A14	`03`			`@1 University of British Columbia @2 Vancouver, British Columbia @3 CAN @Z 3 aut.`
A14	`04`			`@1 Universität Ulm @2 Ulm @3 DEU @Z 5 aut.`
A14	`05`			`@1 McMaster University @2 Hamilton @3 CAN @Z 6 aut.`
A14	`06`			`@1 Division of Neurology, Department of Medicine, University of Toronto @2 Ontario, Canada @3 CAN @Z 7 aut.`
A14	`07`			`@1 Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital @2 Toulouse @3 FRA @Z 8 aut.`
A14	`08`			`@1 CFA-CNRS URA 2210, Service Hospitalier F. Joliot @2 Orsay @3 FRA @Z 9 aut. @Z 10 aut.`
A14	`09`			`@1 Department of Clinical Neurology, University of Innsbruck @2 Innsbruck @3 AUT @Z 11 aut.`
A14	`10`			`@1 University of South Florida and Tampa General Healthcare @2 Tampa, FL @3 USA @Z 12 aut.`
A17	`01`	`1`		`@1 REAL-PET Study Group @3 INC`
A20				`@1 93-101`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16555 @5 354000119867680110`
A44				`@0 0000 @1 © 2003 INIST-CNRS. All rights reserved.`
A45				`@0 30 ref.`
A47	`01`	`1`		`@0 03-0498653`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Annals of neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using ¹⁸F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and ¹⁸F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen ¹⁸F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in ¹⁸F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by ¹⁸F-dopa PET.
C02	`01`	`X`		`@0 002B17G`
C02	`02`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Ropinirole @2 NK @2 FR @5 02`
C03	`02`	`X`	`ENG`	`@0 Ropinirole @2 NK @2 FR @5 02`
C03	`02`	`X`	`SPA`	`@0 Ropinirol @2 NK @2 FR @5 02`
C03	`03`	`X`	`FRE`	`@0 Tomoscintigraphie @5 03`
C03	`03`	`X`	`ENG`	`@0 Emission tomography @5 03`
C03	`03`	`X`	`SPA`	`@0 Tomocentelleografía @5 03`
C03	`04`	`X`	`FRE`	`@0 Dopa @2 NK @2 FR @5 05`
C03	`04`	`X`	`ENG`	`@0 Dopa @2 NK @2 FR @5 05`
C03	`04`	`X`	`SPA`	`@0 Dopa @2 NK @2 FR @5 05`
C03	`05`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 06`
C03	`05`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 06`
C03	`05`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 06`
C03	`06`	`X`	`FRE`	`@0 Putamen @5 08`
C03	`06`	`X`	`ENG`	`@0 Putamen @5 08`
C03	`06`	`X`	`SPA`	`@0 Putamen @5 08`
C03	`07`	`X`	`FRE`	`@0 Cartographie @5 09`
C03	`07`	`X`	`ENG`	`@0 Cartography @5 09`
C03	`07`	`X`	`SPA`	`@0 Cartografía @5 09`
C03	`08`	`X`	`FRE`	`@0 Etude comparative @5 17`
C03	`08`	`X`	`ENG`	`@0 Comparative study @5 17`
C03	`08`	`X`	`SPA`	`@0 Estudio comparativo @5 17`
C03	`09`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 18`
C03	`09`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 18`
C03	`09`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 18`
C03	`10`	`X`	`FRE`	`@0 Positon @5 19`
C03	`10`	`X`	`ENG`	`@0 Positron @5 19`
C03	`10`	`X`	`SPA`	`@0 Positrón @5 19`
C03	`11`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 21`
C03	`11`	`X`	`ENG`	`@0 Dopamine agonist @5 21`
C03	`11`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 21`
C03	`12`	`X`	`FRE`	`@0 Etude double insu @5 22`
C03	`12`	`X`	`ENG`	`@0 Double blind study @5 22`
C03	`12`	`X`	`SPA`	`@0 Estudio doble ciego @5 22`
C03	`13`	`X`	`FRE`	`@0 Homme @5 23`
C03	`13`	`X`	`ENG`	`@0 Human @5 23`
C03	`13`	`X`	`SPA`	`@0 Hombre @5 23`
C03	`14`	`X`	`FRE`	`@0 Pronostic @5 24`
C03	`14`	`X`	`ENG`	`@0 Prognosis @5 24`
C03	`14`	`X`	`SPA`	`@0 Pronóstico @5 24`
C03	`15`	`X`	`FRE`	`@0 Agoniste @5 25`
C03	`15`	`X`	`ENG`	`@0 Agonist @5 25`
C03	`15`	`X`	`SPA`	`@0 Agonista @5 25`
C03	`16`	`X`	`FRE`	`@0 Récepteur dopaminergique D2 @5 26`
C03	`16`	`X`	`ENG`	`@0 D2 Dopamine receptor @5 26 @6 «D2» Dopamine receptor`
C03	`16`	`X`	`SPA`	`@0 Receptor dopaminérgico D2 @5 26`
C03	`17`	`X`	`FRE`	`@0 Aminoacide @5 27`
C03	`17`	`X`	`ENG`	`@0 Aminoacid @5 27`
C03	`17`	`X`	`SPA`	`@0 Aminoácido @5 27`
C03	`18`	`X`	`FRE`	`@0 Catécholamine @5 28`
C03	`18`	`X`	`ENG`	`@0 Catecholamine @5 28`
C03	`18`	`X`	`SPA`	`@0 Catecolamina @5 28`
C03	`19`	`X`	`FRE`	`@0 Captation @5 35`
C03	`19`	`X`	`ENG`	`@0 Uptake @5 35`
C03	`19`	`X`	`SPA`	`@0 Captación @5 35`
C07	`01`	`X`	`FRE`	`@0 Encéphale pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Système nerveux pathologie @5 41`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 41`
N21				`@1 335`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 03-0498653 INIST
ET :	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AU :	WHONE (Alan L.); WATTS (Ray L.); STOESSL (A. Jon); DAVIS (Margaret); RESKE (Sven); NAHMIAS (Claude); LANG (Anthony E.); RASCOL (Olivier); RIBEIRO (Maria J.); REMY (Philippe); POEWE (Werner H.); HAUSER (Robert A.); BROOKS (David J.)
AF :	Faculty of Medicine, Imperial College, Hammersmith Hospital/London/Royaume-Uni (1 aut., 13 aut.); Department of Neurology, Emory University School of Medicine/Atlanta, GA/Etats-Unis (2 aut., 4 aut.); University of British Columbia/Vancouver, British Columbia/Canada (3 aut.); Universität Ulm/Ulm/Allemagne (5 aut.); McMaster University/Hamilton/Canada (6 aut.); Division of Neurology, Department of Medicine, University of Toronto/Ontario, Canada/Canada (7 aut.); Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital/Toulouse/France (8 aut.); CFA-CNRS URA 2210, Service Hospitalier F. Joliot/Orsay/France (9 aut., 10 aut.); Department of Clinical Neurology, University of Innsbruck/Innsbruck/Autriche (11 aut.); University of South Florida and Tampa General Healthcare/Tampa, FL/Etats-Unis (12 aut.)
DT :	Publication en série; Niveau analytique
SO :	Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2003; Vol. 54; No. 1; Pp. 93-101; Bibl. 30 ref.
LA :	Anglais
EA :	Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using ¹⁸F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and ¹⁸F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen ¹⁸F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in ¹⁸F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by ¹⁸F-dopa PET.
CC :	002B17G; 002B02B06
FD :	Parkinson maladie; Ropinirole; Tomoscintigraphie; Dopa; Dopamine; Putamen; Cartographie; Etude comparative; Lévodopa; Positon; Stimulant dopaminergique; Etude double insu; Homme; Pronostic; Agoniste; Récepteur dopaminergique D2; Aminoacide; Catécholamine; Captation
FG :	Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie
ED :	Parkinson disease; Ropinirole; Emission tomography; Dopa; Dopamine; Putamen; Cartography; Comparative study; Levodopa; Positron; Dopamine agonist; Double blind study; Human; Prognosis; Agonist; D2 Dopamine receptor; Aminoacid; Catecholamine; Uptake
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases
SD :	Parkinson enfermedad; Ropinirol; Tomocentelleografía; Dopa; Dopamina; Putamen; Cartografía; Estudio comparativo; Levodopa; Positrón; Estimulante dopaminérgico; Estudio doble ciego; Hombre; Pronóstico; Agonista; Receptor dopaminérgico D2; Aminoácido; Catecolamina; Captación
LO :	INIST-16555.354000119867680110
ID :	03-0498653

Links to Exploration step

Pascal:03-0498653

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation><inist:fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation><inist:fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation><inist:fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">03-0498653</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 03-0498653 INIST</idno>
<idno type="RBID">Pascal:03-0498653</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A43</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</title>
<author><name sortKey="Whone, Alan L" sort="Whone, Alan L" uniqKey="Whone A" first="Alan L." last="Whone">Alan L. Whone</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Watts, Ray L" sort="Watts, Ray L" uniqKey="Watts R" first="Ray L." last="Watts">Ray L. Watts</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name>
<affiliation><inist:fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Davis, Margaret" sort="Davis, Margaret" uniqKey="Davis M" first="Margaret" last="Davis">Margaret Davis</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Reske, Sven" sort="Reske, Sven" uniqKey="Reske S" first="Sven" last="Reske">Sven Reske</name>
<affiliation><inist:fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nahmias, Claude" sort="Nahmias, Claude" uniqKey="Nahmias C" first="Claude" last="Nahmias">Claude Nahmias</name>
<affiliation><inist:fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Ribeiro, Maria J" sort="Ribeiro, Maria J" uniqKey="Ribeiro M" first="Maria J." last="Ribeiro">Maria J. Ribeiro</name>
<affiliation><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name>
<affiliation><inist:fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner H" sort="Poewe, Werner H" uniqKey="Poewe W" first="Werner H." last="Poewe">Werner H. Poewe</name>
<affiliation><inist:fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name>
<affiliation><inist:fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation><inist:fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Annals of neurology</title>
<title level="j" type="abbreviated">Ann. neurol.</title>
<idno type="ISSN">0364-5134</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Aminoacid</term>
<term>Cartography</term>
<term>Catecholamine</term>
<term>Comparative study</term>
<term>D2 Dopamine receptor</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Dopamine agonist</term>
<term>Double blind study</term>
<term>Emission tomography</term>
<term>Human</term>
<term>Levodopa</term>
<term>Parkinson disease</term>
<term>Positron</term>
<term>Prognosis</term>
<term>Putamen</term>
<term>Ropinirole</term>
<term>Uptake</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Ropinirole</term>
<term>Tomoscintigraphie</term>
<term>Dopa</term>
<term>Dopamine</term>
<term>Putamen</term>
<term>Cartographie</term>
<term>Etude comparative</term>
<term>Lévodopa</term>
<term>Positon</term>
<term>Stimulant dopaminergique</term>
<term>Etude double insu</term>
<term>Homme</term>
<term>Pronostic</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Aminoacide</term>
<term>Catécholamine</term>
<term>Captation</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using <sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and <sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen <sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in <sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by <sup>18</sup>
F-dopa PET.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0364-5134</s0>
</fA01>
<fA02 i1="01"><s0>ANNED3</s0>
</fA02>
<fA03 i2="1"><s0>Ann. neurol.</s0>
</fA03>
<fA05><s2>54</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WHONE (Alan L.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WATTS (Ray L.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>STOESSL (A. Jon)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DAVIS (Margaret)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RESKE (Sven)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NAHMIAS (Claude)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>RIBEIRO (Maria J.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>REMY (Philippe)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>POEWE (Werner H.)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>HAUSER (Robert A.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>BROOKS (David J.)</s1>
</fA11>
<fA14 i1="01"><s1>Faculty of Medicine, Imperial College, Hammersmith Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of British Columbia</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Universität Ulm</s1>
<s2>Ulm</s2>
<s3>DEU</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>McMaster University</s1>
<s2>Hamilton</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Neurology, Department of Medicine, University of Toronto</s1>
<s2>Ontario, Canada</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>CFA-CNRS URA 2210, Service Hospitalier F. Joliot</s1>
<s2>Orsay</s2>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Clinical Neurology, University of Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>University of South Florida and Tampa General Healthcare</s1>
<s2>Tampa, FL</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>REAL-PET Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>93-101</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16555</s2>
<s5>354000119867680110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2003 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>30 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>03-0498653</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Annals of neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using <sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and <sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen <sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in <sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by <sup>18</sup>
F-dopa PET.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Tomoscintigraphie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Emission tomography</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Tomocentelleografía</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Dopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Putamen</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Cartographie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Cartography</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Cartografía</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>18</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Positon</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Positron</s0>
<s5>19</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Positrón</s0>
<s5>19</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>21</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>21</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>22</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>22</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Homme</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Human</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Hombre</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>24</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>24</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Agonist</s0>
<s5>25</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Agonista</s0>
<s5>25</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>26</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>26</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>26</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Aminoacide</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Aminoacid</s0>
<s5>27</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Aminoácido</s0>
<s5>27</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>28</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>28</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>28</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Captation</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Uptake</s0>
<s5>35</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Captación</s0>
<s5>35</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>335</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 03-0498653 INIST</NO>
<ET>Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study</ET>
<AU>WHONE (Alan L.); WATTS (Ray L.); STOESSL (A. Jon); DAVIS (Margaret); RESKE (Sven); NAHMIAS (Claude); LANG (Anthony E.); RASCOL (Olivier); RIBEIRO (Maria J.); REMY (Philippe); POEWE (Werner H.); HAUSER (Robert A.); BROOKS (David J.)</AU>
<AF>Faculty of Medicine, Imperial College, Hammersmith Hospital/London/Royaume-Uni (1 aut., 13 aut.); Department of Neurology, Emory University School of Medicine/Atlanta, GA/Etats-Unis (2 aut., 4 aut.); University of British Columbia/Vancouver, British Columbia/Canada (3 aut.); Universität Ulm/Ulm/Allemagne (5 aut.); McMaster University/Hamilton/Canada (6 aut.); Division of Neurology, Department of Medicine, University of Toronto/Ontario, Canada/Canada (7 aut.); Department of Clinical Pharmacology, Clinical Investigation Centre, INSERM U455, Toulouse University Hospital/Toulouse/France (8 aut.); CFA-CNRS URA 2210, Service Hospitalier F. Joliot/Orsay/France (9 aut., 10 aut.); Department of Clinical Neurology, University of Innsbruck/Innsbruck/Autriche (11 aut.); University of South Florida and Tampa General Healthcare/Tampa, FL/Etats-Unis (12 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Annals of neurology; ISSN 0364-5134; Coden ANNED3; Etats-Unis; Da. 2003; Vol. 54; No. 1; Pp. 93-101; Bibl. 30 ref.</SO>
<LA>Anglais</LA>
<EA>Preclinical studies suggest ropinirole (a D2/D3 dopamine agonist) may be neuroprotective in Parkinson's disease (PD), and a pilot clinical study using <sup>18</sup>
F-dopa positron emission tomography (PET) suggested a slower loss of striatal dopamine storage with ropinirole compared with levodopa. This prospective, 2-year, randomized, double-blind, multinational study compared the rates of loss of dopamine-terminal function in de novo patients with clinical and <sup>18</sup>
F-dopa PET evidence of early PD, randomized 1 to 1 to receive either ropinirole or levodopa. The primary outcome measure was reduction in putamen <sup>18</sup>
F-dopa uptake (Ki) between baseline and 2-year PET. Of 186, 162 randomized patients were eligible for analysis. A blinded, central, region-of-interest analysis showed a significantly lower reduction (p = 0.022) in putamen Ki over 2 years with ropinirole (-13.4%; n = 68) compared with levodopa (-20.3%; n = 59; 95% confidence interval [CI], 0.65-13.06). Statistical parametric mapping localized lesser reductions in <sup>18</sup>
F-dopa uptake in the putamen and substantia nigra with ropinirole. The greatest Ki decrease in each group was in the putamen (ropinirole, -14.1%; levodopa, -22.9%; 95% CI, 4.24-13.3), but the decrease was significantly lower with ropinirole compared with levodopa (p < 0.001). Ropinirole is associated with slower progression of PD than levodopa as assessed by <sup>18</sup>
F-dopa PET.</EA>
<CC>002B17G; 002B02B06</CC>
<FD>Parkinson maladie; Ropinirole; Tomoscintigraphie; Dopa; Dopamine; Putamen; Cartographie; Etude comparative; Lévodopa; Positon; Stimulant dopaminergique; Etude double insu; Homme; Pronostic; Agoniste; Récepteur dopaminergique D2; Aminoacide; Catécholamine; Captation</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie</FG>
<ED>Parkinson disease; Ropinirole; Emission tomography; Dopa; Dopamine; Putamen; Cartography; Comparative study; Levodopa; Positron; Dopamine agonist; Double blind study; Human; Prognosis; Agonist; D2 Dopamine receptor; Aminoacid; Catecholamine; Uptake</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases</EG>
<SD>Parkinson enfermedad; Ropinirol; Tomocentelleografía; Dopa; Dopamina; Putamen; Cartografía; Estudio comparativo; Levodopa; Positrón; Estimulante dopaminérgico; Estudio doble ciego; Hombre; Pronóstico; Agonista; Receptor dopaminérgico D2; Aminoácido; Catecolamina; Captación</SD>
<LO>INIST-16555.354000119867680110</LO>
<ID>03-0498653</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A43 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000A43 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:03-0498653
   |texte=   Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri